Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant protein subunit COVID-19 vaccine (CHO cells)
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ZF2001 (brand name Zifivax) is a recombinant protein subunit vaccine developed by Anhui Zhifei Longcom Biopharmaceutical in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences. The vaccine is produced in Chinese Hamster Ovary (CHO) cells and utilizes a tandem repeat dimeric form of the SARS-CoV-2 spike protein receptor-binding domain (RBD) as its antigen, adjuvanted with aluminum hydroxide. It is administered via intramuscular injection, typically following a three-dose schedule at 0, 28, and 56 days. ZF2001 was the first protein subunit COVID-19 vaccine to receive emergency use authorization (EUA) globally, initially in Uzbekistan and subsequently in China. The Sichuan Center for Disease Control and Prevention served as a primary sponsor for its international multicenter Phase III clinical trial (ChiCTR2100050849 / NCT04646525), which evaluated the vaccine's efficacy, safety, and immunogenicity in adults aged 18 and older.
- Brand names
- Zifivax
- Other names
- recombinant protein subunit COVID-19 vaccine (CHO cells)ZFUZVAC2001ZFUZVAC-2001ZFUZVAC 2001Zhifei COVID-19 vaccineRBD-Dimer COVID-19 vaccine
02
Targets
γδ TCR (T-cell receptor)BCR (Immunoglobulin G B Cell Receptor)RBD (SARS-CoV-2 spike receptor-binding domain)ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on recombinant protein subunit COVID-19 vaccine (CHO cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant protein subunit COVID-19 vaccine (CHO cells).